Health technology is attracting fresh capital, but the path from promising innovation to proven clinical value remains a central question.
Wearables draw $4B in investment
Wearables have attracted $4.1B worth of investments this year, according to PitchBook, putting funding back near the sector’s 2021 peak.
- Investors see value beyond hardware sales. As daily wear and subscriptions tick upward, companies are positioning themselves as Personal Health OS built around long-term user data.
- Major deals this year include Whoop’s $575M Series G and Oura’s eventual IPO that could value the company at up to $16B.
Investors say the data collected over time can support personalized coaching, predictive insights, and stronger customer retention. But they also caution that more data doesn’t automatically mean better results.
The coming IPO could offer a major test of how public markets value wearable companies — and whether recurring intelligence can command a premium over device sales.
Precision Neuroscience raises $250M
Precision Neuroscience closed a $250M Series D, bringing its total funding to $430M as it advances its brain-computer interface (BCI) technology.
- The company says it has completed 100+ patient procedures across 18 medical institutions and received FDA clearance for its interface. It also has a partnership with Medtronic and operates its own manufacturing facility in Texas.
- New capital will support the expansion of its clinical program, further FDA review, and the infrastructure needed for commercialization.
Precision is developing a minimally invasive, high-bandwidth interface designed to record brain activity. Its next challenge is moving from clinical procedures and regulatory progress toward broader commercial use.
GRAIL’s cancer blood test nears FDA decision
A FDA advisory panel endorsed GRAIL’S cancer blood test, Galleri, claiming that its benefits outweigh its risks.
- The blood test is designed to detect signals associated with 50+ types of cancer before symptoms appear, to help clinicians identify and investigate cancer earlier.
- However, the panel was nearly split on efficacy, raising concerns about missed cancers and the consequences of false-negative results.
The FDA is expected to make its final decision this year. Galleri is already available to consumers paying out of pocket, and has recently integrated with WHOOP and Function as an add-on.
An FDA authorization could open the door to insurance coverage and bring the test further into clinical oncology, but questions about its performance and how it should be used remain central to the review.
